[39]Pegram MD, Hamilton EP, Tan AR, et al. First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021;20(8):1442-1453. [40]Li JY, Perry SR, Muniz-Med...
[13]FDA Drugs. 2022. https://www.fda.gov. [14]Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436-4441. [15]Krop IE, Kim SB, Gonzále...
Guidelines recommend regular left ventricular ejection fraction (LVEF) assessments and CT's management with cardioprotective drugs (CPD). However, while secondary prevention has already entered clinical practice, primary prevention is still in the research domain. Our aim was to evaluate risk of CT ...
[3] XU B, ZHANG Q, SUN T, et al. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial...
目前FDA批准了五种曲妥珠单抗生物类似物进入美国市场,其他药物正在开发中(见相关链接: https://www.fda.gov/drugs/biosimi-lars/biosimilar-productinformation)。曲妥珠单抗-dkst (OGIVRI,MYL1401O)是首个获得FDA批准(2017年)用于HER2过表达BC和胃肠道(GI)...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
[6]Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021 Oct;32(10):1245-...
Lichtman, Stuart M.Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA;Springer International PublishingDrugs & AgingJasmeet Chadha Singh, Stuart M. Lichtman. (2015) Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs & Aging /...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These dru...
[12] XU B, ZHANG Q, SUN T, et al. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial[J]. BioDrugs, 2021. ...